New Delhi metallo-β-lactamase-producing Acinetobacter isolates among late-onset VAP patients: multidrug-resistant pathogen and poor outcome
spp. are increasingly important microbes involved in late-onset ventilator-associated pneumonia (VAP). The aims of this study were to determine the prevalence of New Delhi metallo-β-lactamase (MβL) ( NDM-1)-producing spp. among late-onset VAP patients in different intensive care units (ICUs) of Meno...
Saved in:
Published in | Infection and drug resistance Vol. 12; pp. 373 - 384 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
New Zealand
Taylor & Francis Ltd
01.01.2019
Dove Medical Press |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | spp. are increasingly important microbes involved in late-onset ventilator-associated pneumonia (VAP).
The aims of this study were to determine the prevalence of New Delhi metallo-β-lactamase (MβL) (
NDM-1)-producing
spp. among late-onset VAP patients in different intensive care units (ICUs) of Menoufia and Kasr Al Ainy University Hospitals, to investigate the possible risk factors contributing to the acquisition of
NDM-1-producing
infection, and to correlate between antimicrobial resistance pattern and therapeutic efficacy as well as clinical outcomes of these patients.
Sixty-four
isolates were collected from mechanically ventilated patients with suspected late-onset VAP and subjected to antimicrobial susceptibility testing. The modified Hodge test (MHT) and combined disk tests (CDT) were applied for
NDM-1 MβL detection.
isolates with phenotypically confirmed MβLs production were subjected to a PCR assay to verify the presence of
NDM-1 gene. The most obvious risk factors for acquisition of carbapenem resistance in VAP patients and treatment outcomes were also analyzed.
Out of 64
isolates, 42 (65.6%) proved to be
NDM-1 positive. The sensitivity and specificity of MHT were 52.38% and 41.67%, while for CDT they were 92.86% and 83.33%, respectively.
isolates showed high susceptibility to colistin (85.7%). The clinical response was better among VAP patients who received combined carbapenem plus colistin therapy than those who received colistin alone. Relapse of infection was detected in 12.5% (8/64) of VAP cases. The reported mortality reached 46.8% (30/64) of which 27 (64.3%) were infected with
NDM-1-positive isolates. Prolonged duration of mechanical ventilation, longer hospital and ICU stays, and prior exposure to antibiotic therapy were by far the most important factors predisposing to carbapenem resistance among VAP patients.
A worldwide spread of
spp. expressing carbapenemases represents a significant threat to the medical community. The current study addressed the high prevalence of
NDM-1-producing
isolates among late-onset VAP patients. |
---|---|
AbstractList | spp. are increasingly important microbes involved in late-onset ventilator-associated pneumonia (VAP).
The aims of this study were to determine the prevalence of New Delhi metallo-β-lactamase (MβL) (
NDM-1)-producing
spp. among late-onset VAP patients in different intensive care units (ICUs) of Menoufia and Kasr Al Ainy University Hospitals, to investigate the possible risk factors contributing to the acquisition of
NDM-1-producing
infection, and to correlate between antimicrobial resistance pattern and therapeutic efficacy as well as clinical outcomes of these patients.
Sixty-four
isolates were collected from mechanically ventilated patients with suspected late-onset VAP and subjected to antimicrobial susceptibility testing. The modified Hodge test (MHT) and combined disk tests (CDT) were applied for
NDM-1 MβL detection.
isolates with phenotypically confirmed MβLs production were subjected to a PCR assay to verify the presence of
NDM-1 gene. The most obvious risk factors for acquisition of carbapenem resistance in VAP patients and treatment outcomes were also analyzed.
Out of 64
isolates, 42 (65.6%) proved to be
NDM-1 positive. The sensitivity and specificity of MHT were 52.38% and 41.67%, while for CDT they were 92.86% and 83.33%, respectively.
isolates showed high susceptibility to colistin (85.7%). The clinical response was better among VAP patients who received combined carbapenem plus colistin therapy than those who received colistin alone. Relapse of infection was detected in 12.5% (8/64) of VAP cases. The reported mortality reached 46.8% (30/64) of which 27 (64.3%) were infected with
NDM-1-positive isolates. Prolonged duration of mechanical ventilation, longer hospital and ICU stays, and prior exposure to antibiotic therapy were by far the most important factors predisposing to carbapenem resistance among VAP patients.
A worldwide spread of
spp. expressing carbapenemases represents a significant threat to the medical community. The current study addressed the high prevalence of
NDM-1-producing
isolates among late-onset VAP patients. Background: Acinetobacter spp. are increasingly important microbes involved in late-onset ventilator-associated pneumonia (VAP). Purpose: The aims of this study were to determine the prevalence of New Delhi metallo-β-lactamase (MβL) (blaNDM-1)-producing Acinetobacter spp. among late-onset VAP patients in different intensive care units (ICUs) of Menoufia and Kasr Al Ainy University Hospitals, to investigate the possible risk factors contributing to the acquisition of blaNDM-1-producing Acinetobacter infection, and to correlate between antimicrobial resistance pattern and therapeutic efficacy as well as clinical outcomes of these patients. Materials and methods: Sixty-four Acinetobacter isolates were collected from mechanically ventilated patients with suspected late-onset VAP and subjected to antimicrobial susceptibility testing. The modified Hodge test (MHT) and combined disk tests (CDT) were applied for blaNDM-1 MβL detection. Acinetobacter isolates with phenotypically confirmed MβLs production were subjected to a PCR assay to verify the presence of blaNDM-1 gene. The most obvious risk factors for acquisition of carbapenem resistance in VAP patients and treatment outcomes were also analyzed. Results: Out of 64 Acinetobacter isolates, 42 (65.6%) proved to be blaNDM-1 positive. The sensitivity and specificity of MHT were 52.38% and 41.67%, while for CDT they were 92.86% and 83.33%, respectively. Acinetobacter isolates showed high susceptibility to colistin (85.7%). The clinical response was better among VAP patients who received combined carbapenem plus colistin therapy than those who received colistin alone. Relapse of infection was detected in 12.5% (8/64) of VAP cases. The reported mortality reached 46.8% (30/64) of which 27 (64.3%) were infected with blaNDM-1-positive isolates. Prolonged duration of mechanical ventilation, longer hospital and ICU stays, and prior exposure to antibiotic therapy were by far the most important factors predisposing to carbapenem resistance among VAP patients. Conclusion: A worldwide spread of Acinetobacter spp. expressing carbapenemases represents a significant threat to the medical community. The current study addressed the high prevalence of blaNDM-1-producing Acinetobacter isolates among late-onset VAP patients. BACKGROUNDAcinetobacter spp. are increasingly important microbes involved in late-onset ventilator-associated pneumonia (VAP). PURPOSEThe aims of this study were to determine the prevalence of New Delhi metallo-β-lactamase (MβL) (blaNDM-1)-producing Acinetobacter spp. among late-onset VAP patients in different intensive care units (ICUs) of Menoufia and Kasr Al Ainy University Hospitals, to investigate the possible risk factors contributing to the acquisition of blaNDM-1-producing Acinetobacter infection, and to correlate between antimicrobial resistance pattern and therapeutic efficacy as well as clinical outcomes of these patients. MATERIALS AND METHODSSixty-four Acinetobacter isolates were collected from mechanically ventilated patients with suspected late-onset VAP and subjected to antimicrobial susceptibility testing. The modified Hodge test (MHT) and combined disk tests (CDT) were applied for blaNDM-1 MβL detection. Acinetobacter isolates with phenotypically confirmed MβLs production were subjected to a PCR assay to verify the presence of blaNDM-1 gene. The most obvious risk factors for acquisition of carbapenem resistance in VAP patients and treatment outcomes were also analyzed. RESULTSOut of 64 Acinetobacter isolates, 42 (65.6%) proved to be blaNDM-1 positive. The sensitivity and specificity of MHT were 52.38% and 41.67%, while for CDT they were 92.86% and 83.33%, respectively. Acinetobacter isolates showed high susceptibility to colistin (85.7%). The clinical response was better among VAP patients who received combined carbapenem plus colistin therapy than those who received colistin alone. Relapse of infection was detected in 12.5% (8/64) of VAP cases. The reported mortality reached 46.8% (30/64) of which 27 (64.3%) were infected with blaNDM-1-positive isolates. Prolonged duration of mechanical ventilation, longer hospital and ICU stays, and prior exposure to antibiotic therapy were by far the most important factors predisposing to carbapenem resistance among VAP patients. CONCLUSIONA worldwide spread of Acinetobacter spp. expressing carbapenemases represents a significant threat to the medical community. The current study addressed the high prevalence of blaNDM-1-producing Acinetobacter isolates among late-onset VAP patients. Asmaa M Elbrolosy,1 Azza Z Labeeb,1 Dina M Hassan2 1Department of Medical Microbiology and Immunology, Faculty of Medicine, Menoufia University, Shebin El-Kom, Egypt; 2Department of Clinical Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt Background: Acinetobacter spp. are increasingly important microbes involved in late-onset ventilator-associated pneumonia (VAP).Purpose: The aims of this study were to determine the prevalence of New Delhi metallo-β-lactamase (MβL) (blaNDM-1)-producing Acinetobacter spp. among late-onset VAP patients in different intensive care units (ICUs) of Menoufia and Kasr Al Ainy University Hospitals, to investigate the possible risk factors contributing to the acquisition of blaNDM-1-producing Acinetobacter infection, and to correlate between antimicrobial resistance pattern and therapeutic efficacy as well as clinical outcomes of these patients.Materials and methods: Sixty-four Acinetobacter isolates were collected from mechanically ventilated patients with suspected late-onset VAP and subjected to antimicrobial susceptibility testing. The modified Hodge test (MHT) and combined disk tests (CDT) were applied for blaNDM-1 MβL detection. Acinetobacter isolates with phenotypically confirmed MβLs production were subjected to a PCR assay to verify the presence of blaNDM-1 gene. The most obvious risk factors for acquisition of carbapenem resistance in VAP patients and treatment outcomes were also analyzed.Results: Out of 64 Acinetobacter isolates, 42 (65.6%) proved to be blaNDM-1 positive. The sensitivity and specificity of MHT were 52.38% and 41.67%, while for CDT they were 92.86% and 83.33%, respectively. Acinetobacter isolates showed high susceptibility to colistin (85.7%). The clinical response was better among VAP patients who received combined carbapenem plus colistin therapy than those who received colistin alone. Relapse of infection was detected in 12.5% (8/64) of VAP cases. The reported mortality reached 46.8% (30/64) of which 27 (64.3%) were infected with blaNDM-1-positive isolates. Prolonged duration of mechanical ventilation, longer hospital and ICU stays, and prior exposure to antibiotic therapy were by far the most important factors predisposing to carbapenem resistance among VAP patients.Conclusion: A worldwide spread of Acinetobacter spp. expressing carbapenemases represents a significant threat to the medical community. The current study addressed the high prevalence of blaNDM-1-producing Acinetobacter isolates among late-onset VAP patients. Keywords: Acinetobacter spp., blaNDM-1, late-onset ventilator-associated pneumonia |
Author | Hassan, Dina M Elbrolosy, Asmaa M Labeeb, Azza Z |
AuthorAffiliation | 2 Department of Clinical Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt 1 Department of Medical Microbiology and Immunology, Faculty of Medicine, Menoufia University, Shebin El-Kom, Egypt, asmaaelbrolosy@yahoo.com |
AuthorAffiliation_xml | – name: 2 Department of Clinical Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt – name: 1 Department of Medical Microbiology and Immunology, Faculty of Medicine, Menoufia University, Shebin El-Kom, Egypt, asmaaelbrolosy@yahoo.com |
Author_xml | – sequence: 1 givenname: Asmaa M surname: Elbrolosy fullname: Elbrolosy, Asmaa M email: asmaaelbrolosy@yahoo.com organization: Department of Medical Microbiology and Immunology, Faculty of Medicine, Menoufia University, Shebin El-Kom, Egypt, asmaaelbrolosy@yahoo.com – sequence: 2 givenname: Azza Z surname: Labeeb fullname: Labeeb, Azza Z email: asmaaelbrolosy@yahoo.com organization: Department of Medical Microbiology and Immunology, Faculty of Medicine, Menoufia University, Shebin El-Kom, Egypt, asmaaelbrolosy@yahoo.com – sequence: 3 givenname: Dina M surname: Hassan fullname: Hassan, Dina M organization: Department of Clinical Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30809098$$D View this record in MEDLINE/PubMed |
BookMark | eNpdUstu1DAUjVARLaUr9sgSGySU4tiJ7bBAGrU8RqoA8dpad5ybmYwcO9gOiH_ga_gQvgkPM1QtXtjXPkfH18fnfnHkvMOieFjRc1bV8tny8sP5x0qJltV3ipOqkqoUreRHN-rj4izGLc2Dt6KW7F5xzKmiLW3VSfHzLX4nl2g3AxkxgbW-_P2rtGASjBCxnILvZjO4NVnkGZNfZQgDGaK3kDASGH0Gd3XpXcREvizekwnSgC7F52ScbRq6MK_LgHGICVzaoRu_RkfAdWTyPhA_J-NHfFDc7cFGPDusp8XnVy8_Xbwpr969Xl4srkpTyyaVIKVsDAqlJBNU9nUvkHeomEQqVWugE6JvFdSmF0pCg6KjkhnKkZteSsZPi-Vet_Ow1VMYRgg_tIdB_z3wYa0hpMFY1JXgILCFFYOmVm120Jh8Td71TVVXJmu92GtN82rEzuRnB7C3RG8jbtjotf-mBZeS1k0WeHIQCP7rjDHpcYgGrQWHfo6a5d8VrKlllamP_6Nu_RxctkozxpmssiU7wad7lgk-xoD9dTMV1bvQ6BwafQhNZj-62f81919E-B-hlsGj |
CitedBy_id | crossref_primary_10_3390_antibiotics8030148 crossref_primary_10_3390_antibiotics12010077 crossref_primary_10_52547_JoMMID_10_4_186 crossref_primary_10_3389_fmicb_2020_589253 crossref_primary_10_3390_antibiotics10111325 crossref_primary_10_22207_JPAM_18_1_59 crossref_primary_10_1371_journal_pone_0256308 crossref_primary_10_3389_fpubh_2022_870354 |
ContentType | Journal Article |
Copyright | 2019. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2019 Elbrolosy et al. This work is published and licensed by Dove Medical Press Limited 2019 |
Copyright_xml | – notice: 2019. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2019 Elbrolosy et al. This work is published and licensed by Dove Medical Press Limited 2019 |
DBID | NPM AAYXX CITATION 3V. 7XB 8C1 8FE 8FH 8FK 8G5 ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH HCIFZ LK8 M2O M7P MBDVC PIMPY PQEST PQQKQ PQUKI PRINS Q9U 7X8 5PM DOA |
DOI | 10.2147/IDR.S186924 |
DatabaseName | PubMed CrossRef ProQuest Central (Corporate) ProQuest Central (purchase pre-March 2016) Public Health Database (Proquest) ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni Edition) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection AUTh Library subscriptions: ProQuest Central ProQuest Natural Science Collection ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep SciTech Premium Collection (Proquest) (PQ_SDU_P3) Biological Sciences ProQuest research library ProQuest Biological Science Journals Research Library (Corporate) ProQuest - Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | PubMed CrossRef Publicly Available Content Database Research Library Prep ProQuest Central Student ProQuest Central Essentials ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Central China ProQuest Central Health Research Premium Collection Natural Science Collection ProQuest Central Korea Biological Science Collection ProQuest Research Library ProQuest Public Health ProQuest Biological Science Collection ProQuest Central Basic ProQuest One Academic Eastern Edition Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest One Academic UKI Edition ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | PubMed Publicly Available Content Database MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: BENPR name: AUTh Library subscriptions: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology Medicine |
EISSN | 1178-6973 |
EndPage | 384 |
ExternalDocumentID | oai_doaj_org_article_163a6e9ab2a5489396cc7e02a5f5141c 10_2147_IDR_S186924 30809098 |
Genre | Journal Article |
GeographicLocations | United States--US Cairo Egypt Egypt |
GeographicLocations_xml | – name: Cairo Egypt – name: United States--US – name: Egypt |
GroupedDBID | --- 0YH 29I 2WC 53G 5VS 8C1 8FE 8FH 8G5 ABUWG ADBBV ADRAZ AFKRA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ C1A CCPQU DIK DWQXO E3Z EBD FYUFA GNUQQ GROUPED_DOAJ GUQSH GX1 HCIFZ HYE IAO IHR IHW IPNFZ ITC KQ8 LK8 M2O M48 M7P M~E NPM O5R O5S OK1 P2P PGMZT PIMPY PQQKQ PROAC RIG RPM UKHRP VDV AAYXX CITATION 3V. 7XB 8FK MBDVC PQEST PQUKI PRINS Q9U 7X8 TDBHL 5PM |
ID | FETCH-LOGICAL-c475t-a7775ce68872607f4f6e3de827e0789cad66f98a4cf687a5e6d072c03e3cf7723 |
IEDL.DBID | RPM |
ISSN | 1178-6973 |
IngestDate | Tue Oct 22 15:12:00 EDT 2024 Tue Sep 17 21:13:56 EDT 2024 Sat Aug 17 01:17:39 EDT 2024 Thu Oct 10 18:09:24 EDT 2024 Thu Sep 26 18:41:50 EDT 2024 Sat Sep 28 08:21:27 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | late-onset ventilator-associated pneumonia blaNDM-1 Acinetobacter spp |
Language | English |
License | The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c475t-a7775ce68872607f4f6e3de827e0789cad66f98a4cf687a5e6d072c03e3cf7723 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-9877-2433 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6377045/ |
PMID | 30809098 |
PQID | 2232716885 |
PQPubID | 3933157 |
PageCount | 12 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_163a6e9ab2a5489396cc7e02a5f5141c pubmedcentral_primary_oai_pubmedcentral_nih_gov_6377045 proquest_miscellaneous_2186625471 proquest_journals_2232716885 crossref_primary_10_2147_IDR_S186924 pubmed_primary_30809098 |
PublicationCentury | 2000 |
PublicationDate | 2019-01-01 |
PublicationDateYYYYMMDD | 2019-01-01 |
PublicationDate_xml | – month: 01 year: 2019 text: 2019-01-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | New Zealand |
PublicationPlace_xml | – name: New Zealand – name: Macclesfield |
PublicationTitle | Infection and drug resistance |
PublicationTitleAlternate | Infect Drug Resist |
PublicationYear | 2019 |
Publisher | Taylor & Francis Ltd Dove Medical Press |
Publisher_xml | – name: Taylor & Francis Ltd – name: Dove Medical Press |
SSID | ssj0000396472 |
Score | 2.2151928 |
Snippet | spp. are increasingly important microbes involved in late-onset ventilator-associated pneumonia (VAP).
The aims of this study were to determine the prevalence... Background: Acinetobacter spp. are increasingly important microbes involved in late-onset ventilator-associated pneumonia (VAP). Purpose: The aims of this... BACKGROUNDAcinetobacter spp. are increasingly important microbes involved in late-onset ventilator-associated pneumonia (VAP). PURPOSEThe aims of this study... Asmaa M Elbrolosy,1 Azza Z Labeeb,1 Dina M Hassan2 1Department of Medical Microbiology and Immunology, Faculty of Medicine, Menoufia University, Shebin El-Kom,... |
SourceID | doaj pubmedcentral proquest crossref pubmed |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | 373 |
SubjectTerms | Acinetobacter Acinetobacter spp Antibiotics Antimicrobial agents Antimicrobial resistance blaNDM-1 Colistin Drug resistance Genes Intensive care Intensive care units Intubation Laboratories late-onset ventilator-associated pneumonia Mechanical ventilation Medical prognosis Medicine Metallo-β-lactamase Methods Mortality Multidrug resistance Multidrug resistant organisms Nosocomial infections Original Research Patients Pneumonia Risk factors Streptococcus infections Ventilator-associated pneumonia Ventilators |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwELZQT1wQ_wQKMlLVU03T2PFPbwulKkigFbSot8hxxt2V2mS1mz30HXiaPgjPxEySbncREhduSeyDkxnPfBPPfMPYTqkAvbiJAjD2Esp4JVwFUVDVpPMZpCCpUPjLV31ypj6f5-drrb4oJ6ynB-4_3D7iBa_B-TLzORGlOB2CgRTvIvr6g9BZ39StBVOdDZZUYZn1nVWs0M7IvjiP2vLsfzr69u479WLK1IY76lj7_wY1_8yYXHNBxw_ZgwE78lG_5kfsHtSP2e64J5--3uOnd7VUiz2-y8d3tNTXT9hPtGf8CC4nU34FLZ23i1834tKH1l-hKxOzjvsVPRkf0WE7bXQicuZT1E4CpLzrS8TpWlAKdst_jMZ84GVdHPIuNbGaLy8ERvCESuuWRicNqij3dcVnTTPnzbJFHYen7Oz44-mHEzH0YhBBmbwV3hiTB9BokzACMlFFDbICm6EsjHXBV1pHZ70KUVvjc9BVarKQSpAhIoKXz9hW3dTwgnGvZUAz4mMk7qMylB50wHnWp9aUyids51Ykxayn3CgwVCHJFSi5YpBcwt6TuFZTiCe7e4DaUwzaU_xLexK2fSvsYti8iwIRU4ZhpLV5wt6uhnHb0VmKr6FZ4hwiCsTg2hwk7HmvG6uVSEThLnU2YWZDazaWujlSTycdtbeWxiDIfvk_3u0Vu4_ozvX_i7bZVjtfwmtEUG35ptssvwEgAxyn priority: 102 providerName: Directory of Open Access Journals – databaseName: AUTh Library subscriptions: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NTttAEB61Qap6qVr6Z0qrrYQ4scX4Z9fuBYUCopVAEYWKm7Vej0kksEPiHHiHPk0fpM_EjL1JmqrqLc6urJVnZueb2Z1vALbyCMmL61IixV4y0iaSaYGl5KrJ1AToY8iFwqdn6uQy-nYVX7mE29Rdq5zvie1GXdSWc-S75MYCwvZJEu-P7yR3jeLTVddC4zGsBRQp-D1YOzg6G5wvsix-yJWWQVeYxy15dr8enn_6zn2YgmjFFbWM_f-CmX_flvzD_Rw_h2cON4p-J-gX8AirdXhy6k7G12F70HFQ3--Ii2VJ1XRHbIvBkp36_iX8pG1NHOLNcCRuseFjd_n7l7wxtjG35NHkuKWAJYcm-vxmtnfmcxYjUlLGpaJtTyT4t-Sb2I340R8IR886_SzaG4rFZHYtKZBncFo1PDqsSVOFqQoxruuJqGcNfXZ8BZfHRxdfTqRrySBtpONGGq11bJHEoCkQ0mVUKgwLTAKNzFtvTaFUmSYmsqVKtIlRFb4OrB9iaEsC8uFr6FV1hW9BGBVa2k1MWTIFUm5zg8rSvMT4ic4j48HWXDrZuGPeyChiYSFmJMTMCdGDA5bcYgrTZbd_1JPrzFlfRqDTKExNHpiY2XZSZS2tmJ5KAox71oPNudwzZ8PTbKlxHnxcDJP18ZGKqbCe0RzmC6QYW-958KZTk8VKQgLjqZ8mHugVBVpZ6upINRq2DN8q1Jqw9sb_l_UOnhJ8S7uE0Cb0mskM3xNEavIPzg4eAGjTFyQ priority: 102 providerName: ProQuest |
Title | New Delhi metallo-β-lactamase-producing Acinetobacter isolates among late-onset VAP patients: multidrug-resistant pathogen and poor outcome |
URI | https://www.ncbi.nlm.nih.gov/pubmed/30809098 https://www.proquest.com/docview/2232716885 https://search.proquest.com/docview/2186625471 https://pubmed.ncbi.nlm.nih.gov/PMC6377045 https://doaj.org/article/163a6e9ab2a5489396cc7e02a5f5141c |
Volume | 12 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JbtswEB3E6aWXonvVpgYLBDmFXrSQUm-OkzQtkEBIk8I3gaLI2IAtGbZ8yD_0a_oh_abOaHHioqdeDFukAQLzyHkjzrwBOEx9g15cWm4w9uK-VD6PMmM5VU1GyjUD41Gh8OWVuLj1v02CyR4EbS1MlbSv01kvny96-Wxa5VYuF7rf5on148ux8KREKtLvQAcB-ihEr45fj4or3boWj7rw9L-eXve-U-sll7rweMiRokEU7jiiSq__XyTz71zJR87n_Dk8a1gjG9WrewF7Jn8JR3EtO31_zG4eqqjWx-yIxQ-C1Pev4CeeZOzUzKcztjAl3bTz37_4XOlSLdCJ8WWl-oo-jI3omp22OEk4sxnikqgoqzoSMfrOKfm6ZD9GMWsUWdefWZWUmK02dxxjd-KjeUmj0wLByVSesWVRrFixKRHd5jXcnp_djC9404WBa18GJVdSykAbgacRxj7S-lYYLzOhKw1J1WuVCWGjUPnailCqwIhsIF098IynLXJ37w3s50Vu3gFTwtN4gChrSfUo1akyQuO8UA1CmfrKgcPWJMmyFttIMEghIyZoxKQxogMnZK7tFFLIrh4Uq7ukwUmCPFMJE6nUVQEJ7ERCa1wx_rLIEYfagYPW2EmzbdcJciUXA8gwDBz4tB3GDUe3KCo3xQbnkEQghtVy6MDbGhvblbTYckDuoGZnqbsjiPFK1LvB9Pv__ucHeIpkLqpfDx3AfrnamI9ImMq0C51wPOzCk5Ozq_i6W712wM8vE3xGW-cPoUwf0g |
link.rule.ids | 230,315,730,783,787,867,888,2109,12235,21400,27936,27937,33278,33279,33756,33757,43591,43817,53804,53806,74342,74630 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1fb9MwELdgk4AXBONfYICRpj3NLMsfO-EFdWxTB2tVjQ7tLXKc81ppS0qbPuw78Gn4IHwm7hK3pQjx1tRWZOXufL87-37H2E4eAXpxZQVg7CUipSORFmAFVU2mOgAfQioU7vVl9yL6fBlfuoTbzF2rXOyJzUZdVIZy5PvoxgLE9kkSf5x8F9Q1ik5XXQuNu2yTqKow-No8PO4PzpdZFj-kSsugLcyjljz7p0fn779SH6YgWnNFDWP_v2Dm37cl_3A_J4_YQ4cbeacV9GN2B8otdq_nTsa32O6g5aC-3ePDVUnVbI_v8sGKnfr2CfuB2xo_guvRmN9ATcfu4tdPca1NrW_Qo4lJQwGLDo136M1k78TnzMeopIRLedOeiNNvQTexa_6tM-COnnX2gTc3FIvp_EpgIE_gtKxpdFShpnJdFnxSVVNezWv87PCUXZwcDz91hWvJIEyk4lpopVRsAMWgMBBSNrISwgKSQAHx1htdSGnTREfGykTpGGThq8D4IYTGIpAPn7GNsirhBeNahgZ3E20tUSDlJtcgDc5LtJ-oPNIe21lIJ5u0zBsZRiwkxAyFmDkheuyQJLecQnTZzR_V9Cpz1pch6NQSUp0HOia2nVQagyvGJ4uA8cB4bHsh98zZ8CxbaZzH3i2H0froSEWXUM1xDvEFYoytDjz2vFWT5UpCBOOpnyYeU2sKtLbU9ZFyPGoYvmWoFGLtl_9f1lt2vzvsnWVnp_0vr9gDhHJpmxzaZhv1dA6vES7V-RtnE78Bz9saHg |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1fb9MwED9BJ028IBh_FhhgpGlPM8vyx054QR1dtQGrqrGhvUWOY6-VtqS06cO-A5-GD8Jn4i5xW4oQb0lsRZbuzvc7--53ALt5ZNCLS8sNxl48kiriaWEsp6rJVAXGNyEVCp8NxMll9OkqvnL5TzOXVrnYE5uNuqg0nZEfoBsLENsnSXxgXVrEsNf_MPnOqYMU3bS6dhr3YUNGIvQ7sHF0PBieL09c_JCqLoO2SI_a8xyc9s7ffaWeTEG05pYa9v5_Qc6_Myf_cEX9R_DQYUjWbYX-GO6Zcgs2z9wt-RbsDVs-6rt9drEqr5rtsz02XDFV3z2BH7jFsZ65GY3ZranpCp7_-slvlK7VLXo3PmnoYNG5sS79mWyfuJ3ZGBWWMCprWhUxeuaUlV2zb90hc1Sts_esyVYspvNrjkE9AdWyptFRhVrLVFmwSVVNWTWvUQTmKVz2jy8-nnDXnoHrSMY1V1LKWBsUicSgSNrIChMWJgmkIQ57rQohbJqoSFuRSBUbUfgy0H5oQm0R1IfPoFNWpdkGpkSocWdR1hIdUq5zZYTGeYnyE5lHyoPdhXSyScvCkWH0QkLMUIiZE6IHRyS55RSizm4-VNPrzFlihgBUCZOqPFAxMe-kQmtcMb5ZBI-H2oOdhdwzZ8-zbKV9HrxdDqMl0vWKKk01xznEHYjxtjz04HmrJsuVhAjMUz9NPJBrCrS21PWRcjxq2L5FKCXi7hf_X9Yb2ERzyL6cDj6_hAeI6tL2nGgHOvV0bl4hcqrz184kfgOuDB5M |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=New+Delhi+metallo-%CE%B2-lactamase-producing+Acinetobacter+isolates+among+late-onset+VAP+patients%3A+multidrug-resistant+pathogen+and+poor+outcome&rft.jtitle=Infection+and+drug+resistance&rft.au=Elbrolosy%2C+Asmaa+M&rft.au=Labeeb%2C+Azza+Z&rft.au=Hassan%2C+Dina+M&rft.date=2019-01-01&rft.issn=1178-6973&rft.eissn=1178-6973&rft.volume=12&rft.spage=373&rft.epage=384&rft_id=info:doi/10.2147%2FIDR.S186924&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1178-6973&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1178-6973&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1178-6973&client=summon |